A detailed history of Lmr Partners LLP transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Lmr Partners LLP holds 67,489 shares of ALNY stock, worth $16.6 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
67,489
Previous 8,971 652.3%
Holding current value
$16.6 Million
Previous $2.18 Million 751.95%
% of portfolio
0.17%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$233.81 - $287.01 $13.7 Million - $16.8 Million
58,518 Added 652.3%
67,489 $18.6 Million
Q2 2024

Aug 14, 2024

SELL
$143.31 - $247.0 $8.94 Million - $15.4 Million
-62,400 Reduced 87.43%
8,971 $2.18 Million
Q1 2024

May 15, 2024

BUY
$146.51 - $198.2 $6.32 Million - $8.56 Million
43,171 Added 153.09%
71,371 $10.7 Million
Q4 2023

Feb 14, 2024

SELL
$151.41 - $196.57 $5.98 Million - $7.77 Million
-39,524 Reduced 58.36%
28,200 $5.4 Million
Q3 2023

Nov 14, 2023

BUY
$170.77 - $211.65 $5.64 Million - $6.99 Million
33,029 Added 95.2%
67,724 $12 Million
Q2 2023

Aug 14, 2023

BUY
$185.01 - $212.05 $2.51 Million - $2.87 Million
13,551 Added 64.09%
34,695 $6.59 Million
Q1 2023

May 15, 2023

BUY
$182.66 - $235.53 $3.86 Million - $4.98 Million
21,144 New
21,144 $4.24 Million
Q3 2022

Nov 14, 2022

SELL
$138.54 - $232.0 $18.6 Million - $31.1 Million
-134,266 Reduced 97.03%
4,107 $822,000
Q2 2022

Aug 15, 2022

BUY
$120.42 - $169.29 $5.57 Million - $7.83 Million
46,259 Added 50.22%
138,373 $20.2 Million
Q1 2022

May 16, 2022

BUY
$127.18 - $173.91 $8.89 Million - $12.2 Million
69,886 Added 314.41%
92,114 $15 Million
Q4 2021

Feb 14, 2022

BUY
$159.56 - $209.29 $3.55 Million - $4.65 Million
22,228 New
22,228 $3.77 Million
Q4 2017

Jan 30, 2018

SELL
$114.49 - $139.98 $5.79 Million - $7.08 Million
-50,588 Closed
0 $0
Q3 2017

Nov 09, 2017

BUY
$72.53 - $118.27 $3.67 Million - $5.98 Million
50,588
50,588 $5.94 Million

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.3B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Lmr Partners LLP Portfolio

Follow Lmr Partners LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Lmr Partners LLP with notifications on news.